Who Owns Aclaris Therapeutics Stock?
NASDAQ: ACRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 87.30%
- Held by insiders
- 2.03%
- Institutional holders
- 217
- Institutions 87.3%
- Insiders 2.0%
- Public and other 10.7%
Who owns Aclaris Therapeutics stock?
Institutional investors own about 87.3% of Aclaris Therapeutics's shares, spread across 217 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 2.03% of ACRS.
The largest institutional holders are RA Capital Management, L.P. (8.02%), BML Capital Management, LLC (6.91%) and Blackrock Inc. (6.54%). Together, the top 10 institutions control 51.0% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their ACRS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ACRS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 12.72M | 8.02% | 0.0% |
| BML Capital Management, LLC | 10.96M | 6.91% | -8.5% |
| Blackrock Inc. | 10.38M | 6.54% | +3.4% |
| Deep Track Capital, Lp | 9.35M | 5.89% | 0.0% |
| Frazier Life Sciences Management, L.P. | 8.73M | 5.50% | +77.2% |
| FMR, LLC | 7.05M | 4.44% | +2145.7% |
| Vivo Capital, LLC | 6.69M | 4.22% | 0.0% |
| Vanguard Capital Management LLC | 5.86M | 3.70% | +0.8% |
| MPM Bioimpact LLC | 5.18M | 3.26% | +396.7% |
| Decheng Capital LLC | 4.04M | 2.55% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ACRS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.24M | 2.68% |
| iShares Trust-iShares Russell 2000 ETF | 3.09M | 1.95% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.93M | 1.22% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.45M | 0.91% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.30M | 0.82% |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 1.14M | 0.72% |
| iShares Trust-iShares Russell 2000 Growth ETF | 969.37K | 0.61% |
| iShares Trust-iShares Biotechnology ETF | 878.49K | 0.55% |
| Fidelity Commonwealth Trust II-Fidelity Enhanced Small Cap Core ETF | 834.44K | 0.53% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 826.70K | 0.52% |
Frequently asked questions
Who is the largest shareholder of Aclaris Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of ACRS, owning 8.02% of shares outstanding (12.72M shares) as of its latest 13F filing.
What percentage of Aclaris Therapeutics is owned by institutions?
Institutions own about 87.3% of ACRS shares and 89.1% of the public float.
How much of Aclaris Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.03% of ACRS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.